- Trial phase
- Phase 1/2
- Time to market
- Several years from potential approval. Regeneron is enrolling a potentially registrational single-arm cohort, plans FDA discussions in the coming months, and intends to initiate a confirmatory randomized Phase 3 trial; even under an accelerated path, market entry would likely be several years away.
- Why 4/10
- No hard dated catalyst (PDUFA, pivotal readout, or FDA decision) is scheduled in the next ~12 months; the next event is data from the potentially registrational ~100-patient LGSOC cohort or the planned confirmatory Phase 3 trial initiation, neither with a set date, and ubamatamab is a mid-stage drug at a large-cap diversified biotech, so the score stays at the default 4.
Watch for updates on the potentially registrational LGSOC cohort enrollment completion and any FDA meeting outcomes regarding the regulatory path. The next major catalyst would be data from the ~100-patient single-arm registrational cohort or the initiation of the planned confirmatory Phase 3 trial, though no specific date has been set.
Price Chart
Executive Summary
Ubamatamab (REGN4018) is Regeneron's investigational MUC16xCD3 bispecific antibody being developed for ovarian cancer, with an initial focus on low-grade serous ovarian cancer (LGSOC). In October 2026, Regeneron reported early Phase 1/2 data at the IGCS 2026 meeting showing a 73% objective response rate (8 of 11 patients) and 11-month median progression-free survival at the 800 mg dose in heavily pretreated LGSOC patients. Regeneron is now enrolling a potentially registrational single-arm cohort of up to 100 patients and plans a confirmatory Phase 3 trial. The drug is still mid-stage with no dated regulatory catalyst, and Regeneron is a large-cap diversified biotech for which ubamatamab is one of many pipeline assets.
How It Works
Ubamatamab is a bispecific antibody, a type of engineered immunotherapy that works like a bridge. One arm of the antibody binds to MUC16, a protein abundant on the surface of ovarian cancer cells, and the other arm binds to CD3, a protein on immune T cells. This physically brings T cells next to the cancer cells and activates them to kill the tumor, using the body's own immune system rather than chemotherapy.
Trial Status
Ubamatamab is in an ongoing Phase 1/2 first-in-human trial (NCT03564340) in recurrent ovarian cancer and other MUC16+ cancers, alone or with cemiplimab. At IGCS 2026 (October 2026), Regeneron reported a 73% ORR and 11-month median PFS in 11 LGSOC patients treated at 800 mg. A potentially registrational LGSOC cohort of up to 100 patients is enrolling, and a separate multi-arm Phase 2 platform study (NCT06787612) is evaluating ubamatamab with or without additional agents in platinum-resistant ovarian cancer.
The Two-Sided Case
Upcoming Catalysts
- Data from the potentially registrational single-arm LGSOC cohort (up to 100 patients), no specific date announced
- FDA discussions on the LGSOC regulatory path, expected in the coming months per Regeneron
- Initiation of the planned confirmatory randomized Phase 3 trial in LGSOC, planned but undated
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report